|Assessment process complete
|In combination with bendamustine followed by obinutuzumab maintenance for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended at the submitted price
The HSE has approved reimbursement following confidential price negotiations October 2017.